TAKEDA PHARMACEUTICAL CO LTD
TAK, TKPHF · Pharmaceutical Preparations · EDGAR filings ↗
Grade
B73Diversified global pharma with top-decile cash generation but depressed returns from amortization, impairments and pipeline setbacks.
Strengths
- Top-decile free cash flow ($5.7B, 97th pct), OCF margin (87th pct) and cash balance (96th pct) — strong, durable cash engine
- Scaled, diversified franchise with high-quartile sector ROA/ROE/ROIC percentiles and solid interest coverage (83rd pct)
Risks
- Very low absolute net margin (2.4%) and ROE (1.6%), with net income -24% on heavy impairments (soticlestat Phase 3 failure, cell-therapy and ALUNBRIG write-downs)
- ENTYVIO selected for Medicare (IRA) price negotiation, broad LOE/pricing pressure and binary R&D outcomes
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $2.6B cash & investments
- Notable holderHeld by 4 notable fund(s): FMR LLC, GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC +1 more (as of 2026-03-31)
Key metrics
Gross margin
65.5%
Operating margin
7.5%
Net margin
2.4%
Return on equity
1.6%
Return on assets
0.8%
ROIC
2.4%
Revenue growth (QoQ)
8.9%
Net-income growth
-24.0%
Debt / equity
0.7×
Interest coverage
2.5×
Current ratio
1.0×
Free cash flow
$5.7B
Tangible book value
$10.8B
Cash & investments
$2.6B
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-27 | Weber Christophe Pierre | Grant | 79K | — |
| 2026-04-27 | Weber Christophe Pierre | Grant | 165K | — |
| 2026-04-27 | Furuta Milano | Grant | 7.8K | — |
| 2026-04-27 | Plump Andrew Stewart | Grant | 212K | — |
| 2026-04-27 | Ricci Gabriele | Grant | 35K | — |
| 2026-04-27 | Bitetti Teresa Marie | Grant | 65K | — |
| 2026-04-27 | Duprey Lauren Rusckowski | Grant | 60K | — |
| 2026-04-27 | Kim Julie So-Young | Grant | 105K | — |
| 2026-04-27 | Platford Giles Richard | Grant | 72K | — |
| 2026-04-27 | Pignagnoli Agosti Marcello | Grant | 28K | — |
| 2025-09-17 | TAKEDA PHARMACEUTICAL CO LTD | U | 6.7M | $1.95 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (0)
Named in the 10-K; linked when we track them.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-06-17 | 2026-03-31 | 0001395064-26-000177 ↗ |
| 20-F | 2025-06-25 | 2025-03-31 | 0001395064-25-000095 ↗ |
| 20-F | 2024-06-26 | 2024-03-31 | 0001395064-24-000086 ↗ |
| 20-F | 2023-06-28 | 2023-03-31 | 0001395064-23-000072 ↗ |
| 20-F | 2022-06-29 | 2022-03-31 | 0001395064-22-000107 ↗ |
| 20-F | 2021-06-29 | 2021-03-31 | 0001395064-21-000140 ↗ |
| 20-F | 2020-06-24 | 2020-03-31 | 0001395064-20-000110 ↗ |
| 20-F | 2019-06-27 | 2019-03-31 | 0001395064-19-000005 ↗ |